RJRuwen Jou

Ruwen Jou

*This is an algorithmically generated author record based on publicly available information.

Ruwen Jou has a total of 131 co-authors. Here are the top co-authors by number of shared publications:

  • Mei-Hua Wu

    Tuberculosis Research Center, Taiwan Centers for Disease Control, Ministry of Health and Welfare Taipei, Taiwan; Reference Laboratory of Mycobacteriology, Taiwan Centers for Disease Control, Ministry of Health and Welfare, Taipei, Taiwan

    8 shared publications
  • Wei-Lun Huang

    Reference Laboratory of Mycobacteriology, Research and Diagnostic Center, Centers for Disease Control, Department of Health, 161 Kun-Yang Street, Nan-Kang, Taipei 115, Taiwan

    8 shared publications
  • Hseuh-Chien Hsiao

    Tuberculosis Research Center, Centers for Disease Control, Ministry of Health and Welfare

    4 shared publications
  • Ming-Chih Yu

    Division of Pulmonary Medicine, Dept of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan School of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei, Taiwan

    4 shared publications
  • Chen-Yuan Chiang

    International Union Against Tuberculosis and Lung Disease, Paris, France

    3 shared publications
  • Huang-Yau Chen

    Reference Laboratory of Mycobacteriology, Research and Diagnostic Center, Centers for Disease Control, 161 Kun-Yang Street, Nan-Kang, Taipei 115, Taiwan, Republic of China

    3 shared publications

Latest Publications

  • Open Access

    Cycloserine resistance among drug-resistant tuberculosis cases in Taiwan

    by Sheng-Han Wu, Hsin-Yi Liu, Kuang-Hung Liu, Hseuh-Chien Hsiao, Ruwen Jou

    Cycloserine (CS) is a widely used drug for drug-resistant tuberculosis (DR-TB) treatment. The World Health Organization (WHO) recently suggested a critical concentration (CC) for CS using the MGIT 960 system (MGIT). To strengthen our DR-TB management program, we performed CS resistance analyses to provide comprehensive drug susceptibility testing (DST). This retrospective study included Mycobacterium tuberculosis complex (MTBC) isolates obtained from 114 rifampin-resistant (RR) and multidrug-resistant (MDR) TB cases. We compared the results of phenotypic DST (pDST) and genotypic DST (gDST) and evaluated the minimum inhibitory concentration (MIC) using both MGIT and the Sensititre MYCOTB MIC Plate (Sensititre). Sanger sequencing and whole-genome sequencing were conducted to analyze the mutations of CS-resistant-associated ald and alr genes. Our results indicated that the optimal consistency with gDST was achieved with the CC of 16 µg/mL for MGIT, which aligns with the WHO recommendations, and the CC of 8 µg/mL for Sensititre. Of the 114 MTBC isolates, we found 5 (4.4%) CS-MGIT-resistant isolates, which all harbored mutations in the alr gene, including three previously known mutations M343T, T20M, L113R, and a novel mutation R243S, whereas seven low-MIC isolates harboring alr Q30R mutations might not be associated with CS resistance. Notably, M1I, E118K, and A184T in the ald gene and L113R, R243S, S261N, and M343T in the alr gene were predicted to have a destabilizing effect, which could interfere with protein functions and induce drug resistance. For accurate routine diagnosis of CS susceptibility, we adopted the CC of 16 µg/mL and suggested an interim 8 µg/mL using MGIT and Sensititre, respectively. IMPORTANCE: To strengthen the DR-TB management program in Taiwan, we performed cycloserine (CS) resistance analyses to enhance treatment outcomes. Of the 114 drug-resistant tuberculosis (DR-TB) isolates, we found 5 (4.4%) CS-MGIT-resistant isolates, with four isolates classified as multidrug-resistant (MDR)-TB and one isolate as Pre-XDR-TB. In addition, we observed all CS-MGIT-resistant isolates harbored mutations in the alr gene, including three previously known high-confidence mutations M343T, T20M, and L113R, as well as the novel R243S mutation. We also found that mutations could lead to CS resistance by disrupting protein stability.


  • A simplified pyrazinamidase test for Mycobacterium tuberculosis pyrazinamide antimicrobial susceptibility testing

    by Hsin-Hua Chan, Yu-Chen Wang, Ruwen Jou

    Pyrazinamide (PZA) is an important first-line drug for tuberculosis (TB) treatment by eradicating the persisting Mycobacterium tuberculosis complex (MTBC). Due to cost and technical challenges, end TB strategies are hampered by the lack of a simple and reliable culture-based PZA antimicrobial susceptibility testing (AST) for routine use. We initially developed a simplified chromogenic pyrazinamidase (PZase) test in the TB reference laboratory using a training set MTBC isolates with various drug-resistant profiles, and validated its performance using consecutive BACTEC MGIT 960 (MGIT)-culture-positive culture in 10 clinical laboratories. The pncA gene Sanger sequencing results were used as the reference, and compared to the MGIT-PZA AST. Differential diagnosis of Mycobacterium bovis was conducted using patented in-house real-time PCR. Of the 106 training isolates, the PZase test and MGIT-PZA AST showed 100.0% and 99.1% concordance as compared to Sanger sequencing, respectively. We found 32.1% (34/106) isolates harbored pncA mutations, including one isolate with silent mutation S65S. For validation, 1,793 clinical isolates were tested including 150 duplicate isolates from specimens of the same cases and 16 isolates with uncharacterized drug resistance (UDR)-associated mutations. Excluding duplicated and UDR isolates, we identified 2.6% (43/1,627) PZA-resistant isolates, including 1.3% (21/1,627) M . bovis isolates. The kappa values were 0.851–1.000. In addition, the accuracy of the PZase test conducted by 10 laboratories was 98.5%–100.0%. Our simplified PZase test demonstrated high concordance with Sanger sequencing and MGIT-PZA AST. Integrating the PZase test into routine first-line AST is effortless and represents an improvement in laboratory services for ending TB. IMPORTANCE: We developed and validated a simple pyrazinamidase (PZase) test for pyrazinamide (PZA) antimicrobial susceptibility testing (AST). Our results demonstrated that the PZase test had high agreement with the pncA gene sequencing and MGIT-PZA AST. Integrating PZase test into routine AST is effortless and represents an improvement in laboratory services for ending TB.


  • Open Access

    Define SNP thresholds for delineation of tuberculosis transmissions using whole-genome sequencing

    by Yu-Xin Xiao, Tai-Hua Chan, Kuang-Hung Liu, Ruwen Jou

    For facilitating tuberculosis (TB) control, we used a whole-genome sequencing (WGS)-based approach to delineate transmission networks in a country with an intermediate burden of TB. A cluster was defined as Mycobacterium tuberculosis isolates with identical genotypes, and an outbreak was defined as clustered cases with epidemiological links (epi-links). To refine a cluster predefined using space oligonucleotide typing and mycobacterial interspersed repetitive unit variable tandem repeat typing, we analyzed one pansusceptible TB (C1) and three multidrug-resistant (MDR)-TB (C2-C4) clusters from different scenarios. Pansusceptible TB cluster (C1) consisting of 28 cases had ≤5 single nucleotide polymorphisms (SNPs) difference between their isolates. C1 was a definite outbreak, with cases attending the same junior high school in 2012. Three MDR-TB clusters (C2-C4) with distinct genotypes were identified, each consisting of 12–22 cases. Some of the cases had either ≤5 or ≤15 SNPs difference with clear or probable epi-links. Of note, even though WGS could effectively assist TB contact tracing, we still observed missing epi-links in some cases within the same cluster. Our results showed that thresholds of ≤5 and ≤15 SNPs difference between isolates were used to categorize definite and probable TB transmission, respectively. Furthermore, a higher SNP threshold might be required to define an MDR-TB outbreak. WGS still needs to be combined with classical epidemiological methods for improving outbreak investigations. Importantly, different SNP thresholds have to be applied to define outbreaks. IMPORTANCE: TB is a chronic disease. Depending on host factors and TB burden, clusters of cases may continue to increase for several years. Conventional genotyping methods overestimate TB transmission, hampering precise detection of outbreaks and comprehensive surveillance. WGS can be used to obtain SNP information of M. tuberculosis to improve discriminative limitations of conventional methods and to strengthen delineation of transmission networks. It is important to define the country-specific SNP thresholds for investigation of transmission. This study demonstrated the use of thresholds of ≤5 and ≤15 SNPs difference between isolates to categorize definite and probable transmission, respectively. Different SNP thresholds should be applied while a higher cutoff was required to define an MDR-TB outbreak. The utilization of SNP thresholds proves to be crucial for guiding public health interventions, eliminating the need for unnecessary public health actions, and potentially uncovering undisclosed TB transmissions.


  • Open Access

    Whole-genome sequencing-based analyses of drug-resistant Mycobacterium tuberculosis from Taiwan

    by Yu-Xin Xiao, Kuang-Hung Liu, Wan-Hsuan Lin, Tai-Hua Chan, Ruwen Jou

    Drug-resistant tuberculosis (DR-TB) posed challenges to global TB control. Whole-genome sequencing (WGS) is recommended for predicting drug resistance to guide DR-TB treatment and management. Nevertheless, data are lacking in Taiwan. Phenotypic drug susceptibility testing (DST) of 12 anti-TB drugs was performed for 200 Mycobacterium tuberculosis isolates. WGS was performed using the Illumina platform. Drug resistance profiles and lineages were predicted in silico using the Total Genotyping Solution for TB (TGS-TB). Using the phenotypic DST results as a reference, WGS-based prediction demonstrated high concordance rates of isoniazid (95.0%), rifampicin (RIF) (98.0%), pyrazinamide (98.5%) and fluoroquinolones (FQs) (99.5%) and 96.0% to 99.5% for second-line injectable drugs (SLIDs); whereas, lower concordance rates of ethambutol (87.5%), streptomycin (88.0%) and ethionamide (84.0%). Furthermore, minimum inhibitory concentrations confirmed that RIF rpoB S450L, FQs gyrA D94G and SLIDs rrs a1401g conferred high resistance levels. Besides, we identified lineage-associated mutations in lineage 1 (rpoB H445Y and fabG1 c-15t) and predominant lineage 2 (rpoB S450L and rpsL K43R). The WGS-based prediction of drug resistance is highly concordant with phenotypic DST results and can provide comprehensive genetic information to guide DR-TB precision therapies in Taiwan.


  • Open Access

    Development and Assessment of a Novel Whole-Gene-Based Targeted Next-Generation Sequencing Assay for Detecting the Susceptibility of Mycobacterium tuberculosis to 14 Drugs

    by Sheng-Han Wu, Yu-Xin Xiao, Hseuh-Chien Hsiao, Ruwen Jou

    We developed and validated a tNGS assay that was the first to target 22 whole genes instead of regions of drug resistance genes and comprehensively detected susceptibility to 14 anti-TB drugs, with great flexibility to include new or repurposed drugs. Notably, we demonstrated that our custom-designed Ion AmpliSeq TB research panel platform had high concordance with pDST and could significantly reduce turnaround time (by approximately 70%) to meet a clinically actionable time frame.


  • Open Access

    Surveillance of multidrug-resistant tuberculosis in Taiwan, 2008–2019

    by Mei-Hua Wu, Hseuh-Chien Hsiao, Po-Wei Chu, Hsin-Hua Chan, Hsiu-Yun Lo, Ruwen Jou


  • Open Access

    Molecular Epidemiological Characteristics of Mycobacterium abscessus Complex Derived from Non-Cystic Fibrosis Patients in Japan and Taiwan

    by Mitsunori Yoshida, Jung-Yien Chien, Kozo Morimoto, Takeshi Kinjo, Akio Aono, Yoshiro Murase, Keiji Fujiwara, Yuta Morishige, Hiroaki Nagano, Ruwen Jou, et al.

    Members of Mycobacterium abscessus complex (MABC) are frequently isolated from patients. Studies have reported that predominant clones of MABC (known as dominant circulating clones; DCCs) are distributed worldwide and transmitted from humans to humans in patients with cystic fibrosis (CF).


  • Open Access

    Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective In Vitro Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolates

    by Koné Kaniga, Rumina Hasan, Ruwen Jou, Edita Vasiliauskienė, Charoen Chuchottaworn, Nazir Ismail, Beverly Metchock, Skaidrius Miliauskas, Nguyen Viet Nhung, Camilla Rodrigues, et al.

    Bedaquiline drug resistance emergence assessment in multidrug-resistant-tuberculosis (MDR-TB) (DREAM) was a 5-year (2015 to 2019) phenotypic drug resistance surveillance study across 11 countries. DREAM assessed the susceptibility of 5,036 MDR-TB isolates of bedaquiline treatment-naive patients to bedaquiline and other antituberculosis drugs by the 7H9 broth microdilution (BMD) and 7H10/7H11 agar dilution (AD) MIC methods.